Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 1626

Dr Evandro de Azambuja - Jules Bordet Institute, Brussels, Belgium

Dr de Azambuja talks with ecancer at the ESMO 2017 Congress about the data presented by Dr Angelo Di Leo from the MONARCH 3 trial looking at abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer. 

For more information watch the press conference, and Dr Di Leo spoke with ecancer about the data here

Supported by a grant from Pfizer Inc.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence